Drug pricing is a universal issue, and despite China’s efforts to rein in drug prices, pockets of high prices persi… https://t.co/8UxinWn28K
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Our pricing and reimbursement research presented at ISPOR Europe
14 November 2018
Milena Izmirlieva
In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact of securing marketing approval under an expedited pathway on pricing and reimbursement outcomes.
Related Posts
-
-
-
-
-
-
-
-
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
As a new one-off gene therapy for SMA nears the US market, effective pricing will be crucial in ensuring sustainabl… https://t.co/H7NpYRf7pg
India's new clinical trial rules establish an accelerated pathway for new drug approvals, but affordability remains… https://t.co/uhVXDZGLfr
Democrats explore creative ways to expand health insurance access with Medicare X https://t.co/kAsNBvtiuz